Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Healthcare costs in the Danish randomised controlled lung cancer CT-screening trial: a registry study

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Patient reported outcome data as performance indicators in surgically treated lung cancer patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Patient-reported outcomes (PROs) in lung cancer: Experiences from a nationwide feasibility study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Early initiated postoperative rehabilitation reduces fatigue in patients with operable lung cancer: A randomized trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Anti-angiogenic-specific adverse events in patients with non-small cell lung cancer treated with nintedanib and docetaxel

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Labour market attachment after mild traumatic brain injury: nationwide cohort study with 5-year register follow-up in Denmark

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Physical discomfort in early pregnancy and postpartum depressive symptoms

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

OBJECTIVES: Low dose computerised tomography (CT) screening for lung cancer can reduce lung-cancer-specific mortality. The objective of this study was to analyse healthcare costs and healthcare utilisation of participants in the Danish lung cancer CT-screening trial (DLCST).

MATERIALS AND METHODS: This registry study was nested in a randomised controlled trial (DLCST). 4104 participants, current or former heavy smokers, aged 50-70 years were randomised to five annual low dose CT scans or usual care during 2004-2010. Total healthcare costs and healthcare utilisation data for both the primary and the secondary healthcare sector were retrieved from public registries from randomisation - September 2011 and compared between (1) the CT-screening group and the control group and, (2) the control group and each of the true-positive, false-positive and true-negative groups.

RESULTS: The median annual costs per participant were significantly higher in the CT-screening group (Euros [EUR] 1342, interquartile range [IQR] 750-2980) compared with the control group (EUR 1190, IQR 590-2692) (p<0.0001). When the cost of the CT-screening programme was excluded, there was no longer a statistically significant difference between the CT-screening group (EUR 1155, IQR 567-2798) and the control group (p=0.52). Analyses according to the diagnostic groups showed that annual costs were 10.57 (95% CI 7.09-15.75) times higher for the true-positive and 1.67 (95% CI 1.20-2.32) times higher for the false-positive group compared with the control group.

CONCLUSION: Low dose lung cancer CT screening increases healthcare costs compared with no screening; this difference was attributable to the costs of the CT-screening programme. Overall healthcare costs were higher for the true-positive and false-positive groups than for the control group, also when excluding the cost of the CT-screening programme. This increase was outweighed by the larger true-negative group showing no significant differences in costs compared with the control group.

Original languageEnglish
JournalLung cancer (Amsterdam, Netherlands)
Volume83
Issue number3
Pages (from-to)347-55
Number of pages9
ISSN0169-5002
DOIs
Publication statusPublished - Mar 2014

    Research areas

  • Aged, Denmark, Early Detection of Cancer, Female, Health Care Costs, Humans, Lung Neoplasms, Male, Mass Screening, Middle Aged, Registries, Tomography, X-Ray Computed

ID: 45071541